← Retour à la une
États-Unis · Magazines éco · Markets Insider (Business Insider)

Polaryx Therapeutics Highlights Participation in NCL Scientific Conference and NTSAD Imagine & Believe Event

Publié par Markets Insider (Business Insider) · États-Unis il y a 2 h
Polaryx Therapeutics Highlights Participation in NCL Scientific Conference and NTSAD Imagine & Believe Event
Markets Insider (Business Insider)

Résumé détaillé

PARAMUS, NJ, Nov. 20, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX) ("Polaryx" or the "Company"), a clinical-stage biotechnology company developing novel,…

PARAMUS, NJ, Nov. 20, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX) ("Polaryx" or the "Company"), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare pediatric lysosomal storage disorders (LSDs), today highlighted its participation in the 9th NCL Translational Science and Therapeutics Conference and the National Tay-Sachs & Allied Diseases Association’s (NTSAD) Imagine & Believe event in the Boston area.

At the NCL conference, held November 11–13, 2026, at the Marriott Boston Quincy in Quincy, Massachusetts, Will Charlton, M.D., M.A.S., Polaryx Therapeutics’ Chief Medical Officer, presented an update on the Company’s development program, including previously published preclinical findings in a CLN3 mouse model. His presentation took place on Friday, November 13, as part of the session titled, “Clinical Program Updates II: Small Molecules, ERTs and Other Therapeutic Approaches.”

Polaryx was also represented by Shrijay Vijayan, Ph.D. MBA, Chief Scientific Officer, and Minsu Kang, Ph.D., Vice President of Clinical Development and Regulatory Affairs and the conference brought together scientists, clinicians, industry representatives and patient advocacy organizations focused on advancing research and therapeutic development for neuronal ceroid lipofuscinoses (NCLs), commonly known as Batten disease. CLN2 and CLN3 disease are among the four indications being evaluated in Polaryx’s SOTERIA Phase 2 basket trial of orally administered PLX-200.

“Advancing therapies for rare pediatric diseases requires close engagement with the scientific community and the families whose lives are affected by these conditions,” said Alex Yang, Polaryx Therapeutics’ Chair and Chief Executive Officer. “Following activation of our first SOTERIA clinical trial site, these events provided an important opportunity to share our development progress and reinforce our commitment to the patient communities we aim to serve.

Members of the…

Début de l'article, extrait de Markets Insider (Business Insider). Pour lire la suite, ouvrez l'article chez le média.

Lire l'article complet sur Markets Insider (Business Insider) Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (markets.businessinsider.com)

À lire aussi